Hadasit Medical Research Services and Development Ltd.

Hadasit Medical Research Services and Development Company

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Ben-Gurion University of the Negev Research and Development Authority

Agricultural Research Organization Ministry of Agriculture

Other

Baxter International Inc.

Pharmacia Ab

Kabi Pharmacia Ab

Trion Pharma Gmbh

Hadasitmedical Research Serv. & Devel. Ltd.

Agricultural Organization Ministry of Agriculture State of Israel

Agricultural Research Org. Ministry of Agriculture (Gov.)

Gazit, Aviv

Slavin, Shimon

Shimon Slavin

Arnon Nagler

Mark Pines

Israel Vlodavsky

Aviv Gazit

Esther Priel

Sara Yitzchak

Lola Weiss

Tatyana Prigozhina

Shimon Gatt

Arie Dagan

David Gross

Olga Gurevitch

Raphael Mechoulam

Gideon A Rodan

Michael Chorev

Horst Lindhofer

Itai A Bab

Ruth Gallily

Dan Gazit

Chaim Lotan

Oded Abramsky

John W Jacobs

Andras Muhlrad

Hiroshi Okamoto

Zvi Greenberg

Nura Mansur

Dimitrios Karussis

Ehud Geller

Eli Hazum

Basan Gowda S Kurkalli

Shoshana Morecki

Arye Shteyer

Mohinder K Sardana

Michael Zeira

Jeremy Zahavi

Jeremy Zahavy

Dan Lehamann

Eran Leitersdorf

Vardiella Meiner

Ronen Durst

The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.

Telomerase activating compounds and methods of use thereof

The present invention relates to a novel class of tri-aryl compounds, compositions comprising the same and processes for the preparation thereof.

Tri-aryl compounds and compositions comprising the same

The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

Synthetic analogs of sphingolipids

Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.

Treating or preventing diabetes with cannabidiol

The present invention refers to a method of treating tumor growth and metastasis in a mammal, the treating comprising administering allogeneic effector cells together with trifunctional bispecific or trispecific antibodies or a combination thereof having the following properties:

Method of treating tumor growth and metastasis by using trifunctional antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy

A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.

Methods of treatment of hematopoietic disorders

Serious hematologic malignancies are treated through high dose or lethal chemotherapy and/or radiation therapy conditioning regimens followed by rescue with allogeneic stem cell transplantation (allo-SCT) or autologous stem cell transplantation (ASCT). These myeloablative/lymphoablative (M/L) treatment regimens involve the elimination of both the patient's hematopoietic stem cells and T-lymphocytes, often leading to serious complications including graft versus host disease (GVHD). The claimed invention addresses some of these problems by providing a conditioning regimen that is designed to eliminate the patient's T-lymphocytes while retaining a functional population of hematopoietic stem cells (HSC). This non-myeloablative/lymphoablative (-/L) conditioning regimen involves the administration of one or more agents such as purine analogs (e.g., fludarabine), alkylating agents (e.g., bisulfan, cyclophosphamide), or anti-leukocyte globulins (e.g., anti-T lymphocyte globulin). After this, a donor-derived allogeneic stem cell preparation is administered to the patient. Patients treated according to the claimed invention develop donor-specific unresponsiveness and relatively fewer complications as compared to standard M/L conditioning regimens. The claimed methodologies should prove useful in the treatment of a number of hematologic malignancies such as chronic myelogenous leukemia, acute myelogenous leukemia, acute lymphoblastic leukemia, and non-Hodgkin's lymphoma.

Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation

The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.

Non-myeloablative tolerogenic treatment

The invention provides an intracoronary stent coated with a quinazolinone derivative of formula (I), wherein n is 1 or 2, R.sub.1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R.sub.2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl, and physiologically acceptable salts thereof, for preventing restenosis after angioplasty.

Intracoronary stents containing quinazolinone derivatives

Allogeneic cell therapy for cancer following allogeneic stem cell

Quinazolinone-containing pharmaceutical compositions for prevention of

Growing community of inventors

Jerusalem, Israel

Shimon Slavin